[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657663":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":28,"studyPopulation":28,"armGroups":39,"interventions":76,"overallOfficials":28,"centralContacts":90,"locations":96,"responsibleParty":113,"collaborators":28,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":28,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":123,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":28,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":28,"overallStatus":99,"whyStopped":28,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},{"fullName":5,"class":6},"Ascletis Pharma Inc","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":28},[9],{"measure":10,"description":11,"timeFrame":12},"Adverse events","A summary of AEs, SAEs and other non-serious adverse events","Baseline and Day 141",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"Cmax of ASC35","Evaluate the peak plasma concentration of ASC35",{"measure":18,"description":19,"timeFrame":12},"Tmax of ASC35","Evaluate the time to reach peak plasma concentration of ASC35",{"measure":21,"description":22,"timeFrame":12},"AUC of ASC35","Evaluate the area under the plasma concentration-time curve of ASC35",{"measure":24,"description":25,"timeFrame":12},"Change From Baseline in Body Weight","Percentage Change From Baseline in Body Weight",{"measure":24,"description":27,"timeFrame":12},"Actual Change From Baseline in Body Weight",null,{"allocation":30,"interventionModel":31,"interventionModelDescription":28,"primaryPurpose":32,"observationalModel":28,"timePerspective":28,"maskingInfo":33},"RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":34,"maskingDescription":28,"whoMasked":35},"TRIPLE",[36,37,38],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[40,47,51,55,59,64,67,70,73],{"label":41,"type":42,"description":43,"interventionNames":44},"SAD Cohort 1","EXPERIMENTAL","SAD Dose 1",[45,46],"Drug: ASC35 Injection B, for subcutaneous use","Drug: ASC35 Placebo Injection B, for subcutaneous use",{"label":48,"type":42,"description":49,"interventionNames":50},"SAD Cohort 2","SAD Dose 2",[45,46],{"label":52,"type":42,"description":53,"interventionNames":54},"SAD Cohort 3","SAD Dose 3",[45,46],{"label":56,"type":42,"description":57,"interventionNames":58},"SAD Cohort 4","SAD Dose 4",[45,46],{"label":60,"type":61,"description":60,"interventionNames":62},"MAD Cohort 0","ACTIVE_COMPARATOR",[63],"Drug: Tirzepatide",{"label":65,"type":42,"description":65,"interventionNames":66},"MAD Cohort 1",[45,46],{"label":68,"type":42,"description":68,"interventionNames":69},"MAD Cohort 2",[45,46],{"label":71,"type":42,"description":71,"interventionNames":72},"MAD Cohort 3",[45,46],{"label":74,"type":42,"description":74,"interventionNames":75},"MAD Cohort 4",[45,46],[77,82,86],{"type":78,"name":79,"description":80,"armGroupLabels":81,"otherNames":28},"DRUG","ASC35 Injection B, for subcutaneous use","ASC35 Injection B is an investigational once-monthly formulation of ASC35 administered by subcutaneous injection.",[65,68,71,74,41,48,52,56],{"type":78,"name":83,"description":84,"armGroupLabels":85,"otherNames":28},"ASC35 Placebo Injection B, for subcutaneous use","ASC35 Placebo Injection B is a placebo injection matching ASC35 Injection B",[65,68,71,74,41,48,52,56],{"type":78,"name":87,"description":88,"armGroupLabels":89,"otherNames":28},"Tirzepatide","Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist administered by subcutaneous injection",[60],[91],{"name":92,"role":93,"phone":94,"phoneExt":28,"email":95},"Ascletis Recruiting","CONTACT","+1 2068073688","clinicaltrials@ascletis.com",[97],{"facility":98,"status":99,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":110,"contacts":111},"Ascletis Clinical Site","RECRUITING","Baltimore","Maryland","21201","United States","US",{"type":106,"coordinates":107},"Point",[108,109],-76.61219,39.29038,{"lat":109,"lon":108},[112],{"name":92,"role":93,"phone":28,"phoneExt":28,"email":95},{"type":114,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100657663","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-asc35-injection-in-participants-with-obesity-or-overweight-100657663",false,"NCT07842640","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight","A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection, for Subcutaneous Use (Once-monthly Formulation) in Adult Participants With Obesity or Overweight","Inclusion Criteria:\n\n* Have given written informed consent to participate in this study in accordance with local regulations and the Institutional Review Boards (IRB) governing the study site.\n* Are between 18 and 65 years of age (both inclusive) at time of screening.\n* No clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and other screening procedures.\n\nExclusion Criteria:\n\n* Have evidence of any clinically significant active or chronic disease.\n* Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), history of ketoacidosis, or hyperosmolar state\u002Fcoma.\n* Have an autoimmune disease, is immunosuppressed or is in any way immunocompromised.\n* Have a history of acute or chronic pancreatitis.\n* Have a known clinically significant gastric emptying abnormality.\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy.\n* Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the Investigator, may preclude the participant from following and completing the protocol.",true,"ALL","18 Years","65 Years",{"count":127,"type":128},84,"ESTIMATED","INTERVENTIONAL",[131],"PHASE1","This randomized, double-blind, placebo-controlled single ascending dose (SAD)\u002F multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection",[134],"Chronic Weight Management","2026-09-21",{"date":137,"type":138},"2026-09-25","ACTUAL",{"date":140,"type":138},"2026-08-27",{"date":142,"type":128},"2027-06",{"name":144,"class":6},"Ascletis Pharma (China) Co., Limited",1]